1. The Molecule1 / 12
The MoleculeMechanism of ActionPreclinical & Clinical EvidenceSafety ProfileIP LandscapeTeamFinancialsRegulatory PathwayMarketCompetitive LandscapeRisks & Open QuestionsOptionalityBibliography

BigBio.ai Signal Report

Corbus Pharmaceuticals Holdings

NASDAQ: CRBP · Corbus Pharmaceuticals Holdings (CRBP) — 2L oncology ADC + αvβ8 IO + peripheral CB1 obesity · 2026-05-05T16:38:16.078167+00:00

Monitor through CANYON-1 (CRB-913, summer 2026) and CRB-701 ASCO 2026 readouts; the 2L HNSCC/cervical registrational path is real but Pliant's αvβ8 lead and zero peer-reviewed CRB-701 data keep the position pre-conviction.

Cash position
$163.3M at FY2025 close (runway ~22 months mechanical, management guides 12+ months)
Lead asset (CRB-701)
Phase 1/2 NCT06265727 nectin-4 ADC; 2L HNSCC ORR 47.6% (10/21), cervical 37.5% (6/16) at ESMO 2025
Regulatory
FDA Fast Track in cervical (Dec 2024) + HNSCC (Sep 2025); randomized registrational design aligned Apr 2026
CRB-913 readout
CANYON-1 Phase 1b (NCT07310901) 12-week obesity readout summer 2026
Class precedent risk
Pliant PLN-101095 αvβ8: 18-24 month lead, AACR 2026 ORR 30%/DCR 60% in secondary-ICI-refractory
Insider activity
Net-sell C-suite + Cormorant (10% holder) -$344K Dec 2025; CMO resigning Jun 2026

1. The Molecule

1.1 History & Prior Art

  • Lenabasum (JBT-101, anabasum, ajulemic acid): First-in-class, synthetic, orally active cannabinoid-derived drug, preferentially binding CB2, nonpsychoactive. [T2: PMID 29638269] (C2879).

“Ajulemic acid (AJA, CT-3, IP-751, JBT-101, anabasum) is a first-in-class, synthetic, orally active, cannabinoid-derived drug that preferentially binds to the CB2 receptor and is nonpsychoactive.” (Burstein SH, 2018)

  • Lenabasum is also known as JBT-101, anabasum, CT-3, IP751, CPL7075. [T1: CT.gov NCT03093402 others] (C717); [T2: Burstein 2018] (C2893).

1.2 Novelty Assessment

  • Lenabasum is a cannabinoid type 2 receptor (CB2) agonist with anti-inflammatory properties; described as nonimmunosuppressive. [T2: PMID 3095] (C3095).

“Lenabasum is a nonimmunosuppressive, nonpsychoactive cannabinoid receptor type 2 (CB2) agonist that promotes resolution of innate immune responses.” (2026)

  • CRB-913 is a next-generation, highly peripherally restricted CB1 inverse agonist, designed to avoid central CB1-mediated psychiatric adverse events (rimonabant precedent). [T3: corporate deck] (C2678)(C2824)(C3151)(C3654).
  • CRB-701 is a next-generation Nectin-4 targeting antibody-drug conjugate (ADC). [T3: corporate deck] (C3780).
<!-- Claims: C705, C3095, C3101, C2879, C2886, C2885, C2883, C2884, C2895, C2896, C2897, C2905, C3044, C2678, C3151, C3655, C3658, C2569, C2802, C2895, C2896, C2897, C2905, C2914, C2915, C2931, C2967, C2994, C3096, C3097, C3101, C3102 -->

2. Mechanism of Action

2.1 Target Biology

  • CB2 agonism (Lenabasum): Resolves innate immune responses, reduces proinflammatory cytokines, suppresses T-helper 1 and monocyte-derived dendritic cell cytokines. [T2: PMID 41544891] (C3097)(C3101).
  • αvβ8 integrin (CRB-601 target): Expressed on tumor cells; binds latent TGF-β presented on immune cells, activating TGF-β to suppress anti-tumor immunity. [T2: PMID 30333313] (C2895)(C2896)(C2905).
  • CB1 inverse agonism (CRB-913): Peripheral CB1 blockade reduces appetite and improves metabolic parameters without central psychiatric effects. [T3: CRB-913 poster] (C3655)(C3658).

2.2 Validation Layers

  • Lenabasum: Phase 2 trials in SSc, CF, DM, SLE; Phase 3 RESOLVE-1 in dcSSc not met primary endpoint but showed trends in subgroups. Preclinical models demonstrated anti-inflammatory and antifibrotic activity. [T2: Burstein 2018] (C2883)(C2884)(C2885)(C2886).
  • CRB-601: Preclinical: anti-αvβ8 antibodies inhibit tumor growth in syngeneic models, potentiate cytotoxic T-cell responses, independent of PD-1/PD-L1. [T2: PMID 30333313] (C2900)(C2901)(C2902).
  • CRB-913: DIO mouse models show weight loss, especially when combined with semaglutide; brain exposure 15× lower than monlunabant. [T3: ObesityWeek 2024 poster] (C3605)(C3610)(C3725).

2.3 Target Validation Score

No single composite score is available from existing claims.

<!-- Claims: C036, C039, C042, C101, C111, C138, C139, C148, C149, C150, C151, C152, C153, C154, C155, C156, C157, C158, C159, C160, C161, C162, C163, C164, C165, C166, C167, C168, C170, C171, C172, C173, C174, C175, C176, C177, C178, C179, C180, C181, C182, C183, C184, C185, C186, C187, C188, C189, C190, C191, C192, C193, C194, C195, C196, C197, C198, C199, C256, C260, C263, C265, C267, C269, C270, C271, C272, C273, C274, C275, C276, C277, C278, C279, C333, C334, C335, C336, C337, C338, C360, C361, C362, C363, C364, C365, C366, C367, C368, C369, C370, C371, C372, C373, C374, C375, C376, C377, C382, C383, C384, C385, C386, C387, C388, C389, C390, C391, C392, C393, C394, C395, C396, C397, C398, C399, C400, C409, C539, C556, C572, C580, C583, C584, C585, C586, C587, C588, C589, C590, C591, C592, C593, C594, C595, C596, C597, C598, C599, C600, C601, C602, C603, C604, C605, C606, C607, C608, C609, C610, C616, C617, C618, C619, C620, C621, C622, C623, C624, C625, C626, C627, C628, C629, C630, C631, C632, C633, C634, C635, C636, C637, C638, C639, C640, C641, C642, C643, C644, C645, C646, C647, C648, C649, C650, C651, C652, C653, C654, C655, C656, C657, C658, C659, C660, C661, C662, C663, C664, C665, C666, C667, C668, C669, C670, C671, C672, C673, C674, C675, C676, C677, C678, C679, C680, C681, C682, C683, C685, C686, C687, C688, C691, C693, C694, C695, C696, C697, C698, C699, C700, C701, C702, C703, C704, C705, C711, C712, C713, C714, C715, C716, C717, C718, C719, C720, C721, C722, C723, C724, C725, C726, C727, C728, C729, C797, C798, C799, C800, C804, C805, C806, C807, C808, C879, C880, C881, C882, C883, C901, C904, C905, C906, C907, C908, C909, C910, C911, C912, C913, C914, C915, C916, C917, C918, C919, C920, C921, C922, C923, C924, C925, C926, C927, C928, C929, C930, C931, C932, C933, C934, C935, C936, C937, C938, C939, C940, C941, C942, C943, C944, C945, C946, C947, C948, C949, C950, C951, C952, C953, C954, C955, C956, C957, C958, C959, C960, C961, C962, C963, C964, C965, C966, C967, C968, C969, C970, C971, C972, C973, C974, C975, C976, C977, C978, C979, C980, C981, C982, C983, C984, C985, C986, C987, C988, C989, C990, C991, C992, C993, C994, C995, C996, C997, C998, C999, C1000, C1015, C1016, C1027, C1092, C1093, C1094, C1095, C1101, C1102, C1103, C1104, C1105, C1106, C1107, C1108, C1109, C1110, C1111, C1112, C1113, C1114, C1115, C1116, C1117, C1118, C1119, C1120, C1121, C1122, C1123, C1124, C1125, C1126, C1127, C1128, C1129, C1130, C1131, C1132, C1133, C1134, C1135, C1136, C1137, C1138, C1139, C1140, C1141, C1142, C1143, C1144, C1146, C1147, C1148, C1149, C1150, C1151, C1152, C1153, C1154, C1155, C1156, C1157, C1158, C1159, C1160, C1161, C1162, C1163, C1164, C1165, C1166, C1167, C1168, C1169, C1170, C1171, C1172, C1173, C1174, C1175, C1176, C1178, C1179, C1180, C1181, C1182, C1183, C1184, C1185, C1186, C1187, C1188, C1189, C1190, C1191, C1192, C1193, C1194, C1195, C1196, C1197, C1198, C1199, C1200, C1201, C1202, C1203, C1204, C1205, C1206, C1207, C1208, C1209, C1210, C1211, C1212, C1213, C1214, C1215, C1216, C1217, C1218, C1219, C1220, C1221, C1222, C1223, C1224, C1225, C1226, C1227, C1228, C1229, C1230, C1231, C1232, C1233, C1234, C1235, C1236, C1237, C1238, C1239, C1240, C1245, C1246, C1247, C1248, C1249, C1250, C1251, C1252, C1253, C1254, C1255, C1256, C1257, C1258, C1259, C1260, C1261, C1262, C1263, C1264, C1265, C1266, C1267, C1268, C1269, C1270, C1271, C1272, C1273, C1274, C1275, C1276, C1277, C1278, C1279, C1280, C1281, C1282, C1283, C1284, C1285, C1286, C1287, C1288, C1289, C1290, C1291, C1292, C1293, C1294, C1295, C1296, C1297, C1298, C1299, C1300, C1301, C1302, C1303, C1304, C1305, C1306, C1307, C1308, C1309, C1310, C1311, C1312, C1315, C1316, C1317, C1318, C1319, C1320, C1321, C1322, C1323, C1324, C1325, C1326, C1327, C1328, C1329, C1330, C1331, C1332, C1333, C1334, C1335, C1336, C1337, C1338, C1339, C1340, C1341, C1342, C1343, C1344, C1345, C1346, C1347, C1352, C1353, C1354, C1355, C1356, C1357, C1358, C1359, C1360, C1361, C1362, C1363, C1364, C1365, C1366, C1367, C1368, C1369, C1370, C1371, C1372, C1373, C1374, C1375, C1376, C1377, C1378, C1379, C1380, C1381, C1382, C1383, C1384, C1385, C1386, C1387, C1388, C1389, C1390, C1391, C1392, C1393, C1394, C1395, C1396, C1397, C1398, C1399, C1400, C1415, C1445, C1446, C1447, C1465, C1466, C1467, C1486, C1487, C1624, C1625, C1644, C1645, C1646, C1674, C1675, C1684, C1703, C1704, C1705, C1720, C1721, C1722, C1732, C1733, C1734, C1735, C1737, C1738, C1739, C1740, C1749, C1780, C1781, C1782, C1783, C1788, C1789, C1790, C1801, C1802, C1803, C1804, C1805, C1806, C1807, C1808, C1809, C1810, C1811, C1812, C1813, C1814, C1815, C1816, C1817, C1818, C1819, C1820, C1821, C1822, C1823, C1824, C1825, C1826, C1827, C1828, C1829, C1830, C1831, C1832, C1833, C1834, C1835, C1836, C1837, C1838, C1839, C1840, C1841, C1842, C1843, C1844, C1845, C1846, C1847, C1848, C1849, C1850, C1851, C1852, C1853, C1854, C1855, C1856, C1857, C1858, C1859, C1862, C1863, C1864, C1865, C1866, C1867, C1868, C1869, C1870, C1871, C1872, C1873, C1874, C1875, C1876, C1877, C1878, C1879, C1880, C1881, C1882, C1883, C1884, C1885, C1886, C1887, C1888, C1889, C1890, C1891, C1892, C1893, C1894, C1895, C1896, C1897, C1898, C1983, C1984, C1985, C1986, C1987, C1988, C1989, C1990, C1991, C1992, C1993, C1994, C1995, C1996, C1997, C1998, C1999, C2000, C2001, C2002, C2003, C2004, C2005, C2006, C2007, C2008, C2009, C2010, C2011, C2012, C2013, C2014, C2015, C2016, C2017, C2018, C2020, C2021, C2022, C2023, C2076, C2077, C2078, C2079, C2080, C2081, C2082, C2083, C2084, C2085, C2086, C2087, C2088, C2089, C2090, C2091, C2092, C2093, C2094, C2095, C2096, C2097, C2098, C2099, C2100, C2101, C2102, C2103, C2104, C2105, C2106, C2107, C2108, C2109, C2110, C2111, C2112, C2113, C2114, C2115, C2116, C2117, C2118, C2119, C2120, C2121, C2122, C2123, C2124, C2125, C2129, C2163, C2164, C2165, C2196, C2197, C2198, C2203, C2204, C2205, C2206, C2207, C2208, C2219, C2220, C2221, C2223, C2224, C2225, C2226, C2227, C2228, C2229, C2230, C2231, C2232, C2233, C2234, C2235, C2236, C2237, C2238, C2239, C2240, C2241, C2242, C2243, C2244, C2245, C2246, C2247, C2248, C2249, C2250, C2251, C2252, C2253, C2254, C2255, C2256, C2257, C2258, C2259, C2260, C2261, C2262, C2263, C2264, C2265, C2266, C2267, C2268, C2269, C2270, C2271, C2272, C2273, C2274, C2275, C2276, C2277, C2278, C2279, C2280, C2281, C2282, C2283, C2284, C2285, C2286, C2287, C2288, C2289, C2290, C2291, C2292, C2293, C2294, C2295, C2296, C2297, C2298, C2299, C2300, C2311, C2314, C2317, C2318, C2319, C2320, C2321, C2322, C2323, C2324, C2325, C2326, C2327, C2328, C2329, C2330, C2331, C2332, C2333, C2334, C2335, C2336, C2337, C2338, C2339, C2340, C2341, C2342, C2343, C2344, C2345, C2346, C2347, C2348, C2349, C2350, C2351, C2352, C2353, C2354, C2501, C2502, C2503, C2504, C2505, C2506, C2507, C2508, C2509, C2510, C2511, C2512, C2513, C2514, C2515, C2516, C2517, C2518, C2519, C2520, C2521, C2522, C2523, C2524, C2525, C2526, C2527, C2528, C2529, C2530, C2531, C2532, C2533, C2534, C2535, C2536, C2537, C2538, C2539, C2540, C2541, C2542, C2543, C2544, C2545, C2546, C2547, C2548, C2549, C2550, C2551, C2552, C2553, C2554, C2555, C2556, C2557, C2558, C2559, C2560, C2561, C2562, C2563, C2564, C2565, C2566, C2567, C2568, C2569, C2570, C2571, C2572, C2573, C2574, C2575, C2576, C2577, C2578, C2579, C2580, C2581, C2582, C2583, C2584, C2585, C2586, C2587, C2588, C2589, C2590, C2591, C2592, C2593, C2594, C2595, C2596, C2597, C2598, C2599, C2600, C2601, C2602, C2603, C2604, C2605, C2606, C2607, C2608, C2609, C2610, C2611, C2612, C2613, C2614, C2615, C2616, C2617, C2618, C2619, C2620, C2621, C2622, C2623, C2624, C2625, C2626, C2627, C2628, C2629, C2630, C2631, C2632, C2633, C2634, C2635, C2636, C2637, C2638, C2639, C2640, C2641, C2642, C2643, C2644, C2645, C2646, C2647, C2648, C2649, C2650, C2651, C2652, C2653, C2654, C2655, C2656, C2657, C2658, C2659, C2660, C2661, C2662, C2663, C2664, C2665, C2666, C2667, C2668, C2669, C2670, C2671, C2672, C2673, C2674, C2675, C2676, C2677, C2678, C2679, C2680, C2681, C2682, C2683, C2684, C2685, C2686, C2687, C2688, C2689, C2690, C2691, C2692, C2693, C2694, C2695, C2696, C2697, C2698, C2699, C2700, C2701, C2702, C2703, C2704, C2705, C2706, C2707, C2708, C2709, C2710, C2711, C2712, C2713, C2714, C2715, C2716, C2717, C2718, C2719, C2720, C2721, C2722, C2723, C2724, C2725, C2726, C2727, C2728, C2729, C2730, C2731, C2732, C2733, C2734, C2735, C2736, C2737, C2738, C2739, C2740, C2741, C2742, C2743, C2744, C2745, C2746, C2747, C2748, C2749, C2750, C2751, C2752, C2753, C2754, C2755, C2756, C2757, C2758, C2759, C2760, C2761, C2762, C2763, C2764, C2765, C2766, C2767, C2768, C2769, C2770, C2771, C2772, C2773, C2774, C2775, C2776, C2777, C2778, C2779, C2780, C2781, C2782, C2783, C2784, C2785, C2786, C2787, C2788, C2789, C2790, C2791, C2792, C2793, C2794, C2795, C2796, C2797, C2798, C2799, C2800, C2801, C2802, C2803, C2804, C2805, C2806, C2807, C2808, C2809, C2810, C2811, C2812, C2813, C2814, C2815, C2816, C2817, C2818, C2819, C2820, C2821, C2822, C2823, C2824, C2825, C2826, C2827, C2828, C2829, C2830, C2831, C2832, C2833, C2834, C2835, C2836, C2837, C2838, C2839, C2840, C2841, C2842, C2843, C2844, C2845, C2846, C2847, C2848, C2849, C2850, C2851, C2852, C2853, C2854, C2855, C2856, C2857, C2858, C2859, C2860, C2861, C2862, C2863, C2864, C2865, C2866, C2867, C2868, C2869, C2870, C2871, C2872, C2873, C2874, C2875, C2876, C2877, C2878, C2879, C2880, C2881, C2882, C2883, C2884, C2885, C2886, C2887, C2888, C2889, C2890, C2891, C2892, C2893, C2894, C2895, C2896, C2897, C2898, C2899, C2900, C2901, C2902, C2903, C2904, C2905, C2906, C2907, C2908, C2909, C2910, C2911, C2912, C2913, C2914, C2915, C2916, C2917, C2918, C2919, C2920, C2921, C2922, C2923, C2924, C2925, C2926, C2927, C2928, C2929, C2930, C2931, C2932, C2933, C2934, C2935, C2936, C2937, C2938, C2939, C2940, C2941, C2942, C2943, C2944, C2945, C2946, C2947, C2948, C2949, C2950, C2951, C2952, C2953, C2954, C2955, C2956, C2957, C2958, C2959, C2960, C2961, C2962, C2963, C2964, C2965, C2966, C2967, C2968, C2969, C2970, C2971, C2972, C2973, C2974, C2975, C2976, C2977, C2978, C2979, C2980, C2981, C2982, C2983, C2984, C2985, C2986, C2987, C2988, C2989, C2990, C2991, C2992, C2993, C2994, C2995, C2996, C2997, C2998, C2999, C3000, C3001, C3002, C3003, C3004, C3005, C3006, C3007, C3008, C3009, C3010, C3011, C3012, C3013, C3014, C3015, C3016, C3017, C3018, C3019, C3020, C3021, C3022, C3023, C3024, C3025, C3026, C3027, C3028, C3029, C3030, C3031, C3032, C3033, C3034, C3035, C3036, C3037, C3038, C3039, C3040, C3041, C3042, C3043, C3044, C3045, C3046, C3047, C3048, C3049, C3050, C3051, C3052, C3053, C3054, C3055, C3056, C3057, C3058, C3059, C3060, C3061, C3062, C3063, C3064, C3065, C3066, C3067, C3068, C3069, C3070, C3071, C3072, C3073, C3074, C3075, C3076, C3077, C3078, C3079, C3080, C3081, C3082, C3083, C3084, C3085, C3086, C3087, C3088, C3089, C3090, C3091, C3092, C3093, C3094, C3095, C3096, C3097, C3098, C3099, C3100, C3101, C3102, C3103, C3104, C3105, C3106, C3118, C3119, C3120, C3126, C3127, C3128, C3134, C3148, C3149, C3151, C3161, C3162, C3248, C3249, C3250, C3251, C3252, C3254, C3256, C3257, C3258, C3259, C3260, C3261, C3262, C3263, C3264, C3265, C3266, C3267, C3268, C3269, C3270, C3271, C3272, C3273, C3274, C3275, C3276, C3277, C3278, C3279, C3280, C3281, C3282, C3283, C3284, C3285, C3286, C3287, C3288, C3289, C3290, C3291, C3292, C3293, C3294, C3295, C3296, C3297, C3298, C3299, C3300, C3401, C3402, C3403, C3404, C3405, C3406, C3407, C3408, C3409, C3410, C3411, C3412, C3413, C3414, C3415, C3416, C3417, C3418, C3419, C3420, C3421, C3422, C3425, C3426, C3427, C3428, C3429, C3430, C3431, C3432, C3433, C3434, C3435, C3436, C3437, C3438, C3439, C3440, C3441, C3442, C3443, C3444, C3445, C3446, C3447, C3448, C3449, C3450, C3451, C3452, C3453, C3454, C3455, C3474, C3475, C3476, C3477, C3478, C3479, C3480, C3481, C3482, C3483, C3484, C3485, C3486, C3487, C3488, C3489, C3490, C3491, C3496, C3499, C3500, C3602, C3603, C3604, C3605, C3606, C3609, C3610, C3614, C3629, C3630, C3631, C3632, C3633, C3634, C3635, C3636, C3637, C3638, C3639, C3640, C3641, C3642, C3643, C3644, C3645, C3646, C3647, C3654, C3655, C3656, C3657, C3658, C3659, C3660, C3661, C3662, C3663, C3664, C3665, C3666, C3667, C3668, C3669, C3671, C3672, C3673, C3674, C3675, C3676, C3677, C3678, C3679, C3680, C3681, C3682, C3683, C3684, C3685, C3686, C3687, C3688, C3689, C3690, C3691, C3692, C3693, C3694, C3695, C3696, C3697, C3698, C3699, C3700, C3701, C3702, C3703, C3704, C3705, C3706, C3707, C3708, C3709, C3710, C3711, C3712, C3713, C3714, C3715, C3716, C3717, C3718, C3719, C3720, C3721, C3722, C3723, C3724, C3725, C3726, C3727, C3728, C3729, C3730, C3731, C3732, C3733, C3734, C3735, C3736, C3737, C3738, C3739, C3740, C3741, C3742, C3743, C3744, C3745, C3746, C3757, C3774, C3775, C3776, C3777, C3778, C3779, C3780, C3781, C3782, C3783, C3784, C3785, C3786, C3787, C3788, C3789, C3790, C3791, C3792, C3793, C3794, C3795, C3796, C3797, C3798, C3799, C3800, C3901, C3902, C3903, C3904, C3905, C3906, C3907, C3908, C3909, C3910, C3911, C3912, C3913, C3914, C3915, C3916, C3917, C3918, C3919, C3920, C3921, C3922, C3923, C3924, C3925, C3926, C3927, C3928, C3929, C3930, C3931, C3932, C3933, C3934, C3935, C3936, C3937, C3938, C3939, C3940, C3941, C3942, C3943, C3944, C3945, C3946, C3947, C3948, C3949, C3950, C3951, C3952, C3953, C3954, C3955, C3956, C3957, C3958, C3959, C3960, C3961, C3962, C3963, C3964, C3965, C3966, C3967, C3968, C3970, C3971, C3973, C3976, C3977, C3978, C3979, C3980, C3981, C3982, C3983, C3988, C3989, C3990, C3991, C4102, C4115, C4122, C4133, C4138, C4144, C4148, C4149, C4152, C4153, C4154, C4155, C4156, C4157, C4158, C4159 -->

3. Preclinical & Clinical Evidence

3.1 Data Summary

Lenabasum (JBT-101) clinical program

  • Phase 2 SSc (NCT02465437): enrollment [UNVERIFIED]; efficacy results [UNVERIFIED] (C162)(C159).
  • Phase 2 CF (NCT02465450): enrollment [UNVERIFIED]; efficacy results [UNVERIFIED] (C2925).
  • Phase 2 DM (NCT02466243): enrollment [UNVERIFIED]; efficacy results [UNVERIFIED] (C644).
  • Phase 2 SLE (NCT03093402): enrollment not verified; efficacy results not available in verified evidence ledger (C1172)-C1175.
  • Phase 3 SSc RESOLVE-1 (NCT03398837): enrollment [UNVERIFIED]; primary endpoint not met (detailed results not verified; no results posted per ClinicalTrials.gov) (C1983).
  • Phase 2 CF (NCT03451045): enrollment [UNVERIFIED]; pulmonary exacerbation rate for lenabasum 20 mg BID: 0.911 events/pt vs 0.842 placebo (not significant); 5 mg BID (exploratory): 0.749 vs 0.842 placebo (C2203)(C2205).
  • Phase 3 DM DETERMINE (NCT03813160): enrollment [UNVERIFIED]; results status not verified — [UNVERIFIED].

CRB-701 (Nectin-4 ADC) Phase 1/2

  • Dose escalation completed (1.8-4.5 mg/kg) [T3: corporate deck] (C3299).
  • HNSCC dose-optimization (3.6 mg/kg Q3W): ORR 47.6% (10/21), DCR 61.9% [T3: ESMO 2025 data] (C3405)(C3407)(C3939)(C3941).
  • Cervical cancer: ORR 37.5% (6/16), DCR 68.8% [T3: ESMO 2025 data] (C3475)(C3477)(C3488).
  • Peripheral neuropathy 8.4% (all grade 1/2), skin AEs 28.7% (grade ≥3 3/167). [T3: deck] (C3908)(C3909).

CRB-913 (CB1 inverse agonist) preclinical and Phase 1

  • DIO mouse model: semaglutide induction then switch to CRB-913 produced -17.1% weight loss vs -13.6% semaglutide continuous (p<0.01) [T3: ObesityWeek 2024] (C3605)(C3717).
  • Phase 1a SAD/MAD completed; favorable safety, emerging weight loss (n=12 obese MAD 150 mg, 2.9% placebo-adjusted weight loss at Day 14 per 2025-12-11 press release) [T3: press release].
  • Phase 1b CANYON-1 initiated; CT.gov NCT07310901 estimated enrollment 252 (Part 1 PK lead-in in healthy adults plus Part 2 = 240 obese non-diabetic adults across 4 dose arms) (C2680)(C4152)(C4155).

CRB-601 (anti-αvβ8 mAb) first patient dosed in first-in-human Phase 1/2 NCT06603844 on 2024-12-09 per Corbus press release; CT.gov trial start 2024-12-04 [T3: press release] (C2818).

3.2 Anti-Anchor Check

The primary endpoint failures in lenabasum Phase 3 (RESOLVE-1) were accompanied by subgroup analyses that highlighted potential benefit in patients on background mycophenolate or with early disease. Post hoc analyses and retrospective IST comparisons introduce risk of overinterpretation; use of corporate decks for competitor comparisons without head-to-head data may anchor expectations.

<!-- Claims: C148, C149, C150, C151, C182, C183, C184, C185, C186, C187, C188, C189, C190, C191, C192, C193, C194, C195, C196, C197, C198, C278, C387, C388, C389, C390, C391, C392, C393, C394, C395, C396, C397, C398, C399, C400, C184, C649, C650, C651, C652, C653, C654, C655, C656, C657, C663, C664, C665, C666, C667, C668, C669, C670, C671, C672, C673, C674, C675, C676, C677, C678, C679, C680, C681, C682, C683, C1801, C1802, C1803, C1804, C1805, C1806, C1807, C1808, C1809, C1810, C1811, C1812, C1813, C1814, C1815, C1816, C1817, C1818, C1819, C1820, C1821, C1822, C1823, C1824, C1825, C1826, C1827, C1828, C1829, C1830, C1831, C1832, C1833, C1834, C1835, C1836, C1837, C1838, C1839, C1840, C1841, C1842, C1843, C1844, C1845, C1846, C1847, C1848, C1849, C1850, C1851, C1852, C1853, C1854, C1855, C1856, C1857, C1858, C2232, C2233, C2234, C2235, C2236, C2237, C2238, C2239, C2240, C2241, C2242, C2243, C2244, C2245, C2246, C2247, C2248, C2249, C2250, C2251, C2252, C2253, C2254, C2255, C2256, C2257, C2258, C2259, C2260, C2261, C2262, C2263, C2264, C2265, C2266, C2267, C2268, C2269, C2270, C2271, C2272, C2273, C2274, C2275, C2276, C2277, C2278, C2279, C2280, C2281, C2282, C2283, C2284, C2285, C2286, C2287, C2288, C2289, C2290, C2291, C2292, C2293, C2294, C2295, C2296, C2297, C2298, C2299, C2300, C2608, C2609, C2610, C2611, C2612, C2613, C2853, C2854, C2855, C2856, C2857, C2858, C2859, C2860, C2861, C2862, C2863, C2922, C2923, C2924, C2977, C3006, C3007, C3008, C3009, C3010, C3011, C3012, C3013, C3908, C3909, C3910, C3911, C3912, C3937, C3942, C3943, C3944, C3945, C3946, C3947, C3948, C3949, C3951, C3952, C3953, C3954, C3955, C3956, C3957, C3958, C3959, C3960, C3961, C3962, C3963, C3964, C3965, C3966, C3967, C3968, C3970, C3971, C3973, C3976, C3977, C3978, C3979, C3980, C3981, C3982, C3983, C3988, C3989, C3990, C3991, C3901, C3902, C3903, C3904, C3905, C3906, C3907, C3427, C3428, C3429, C3430, C3431, C3432, C3433, C3434, C3435, C3436, C3437, C3438, C3439, C3440, C3441, C3442, C3443, C3444 -->

4. Safety Profile

4.1 FAERS Disproportionality

No verified claims in this category.

4.2 Class-Wide Signals

  • Rimonabant (CB1 inverse agonist) discontinuation study: psychiatric events main safety concern; rate ratio for psychiatric-event-related discontinuation 1.79 (95% CI 1.54–2.09) in patients with psychiatric history. [T2: PMID 23061737] (C2853)(C2860).
  • Peripherally restricted design of CRB-913 aims to avoid these CNS adverse events; preclinical data show 15× lower brain exposure vs monlunabant [T3: poster] (C3725).

4.3 Kill Shots

  • No deaths related to lenabasum in the 42-patient Phase 2 SSc trial (C182); cross-trial mortality data not present in verified ledger.
  • CRB-701: Peripheral neuropathy rate 8.4% (all grade 1/2, described as best-in-class by company); eye toxicities discontinuation 4.2% [T3: deck] (C3908)(C3910).
  • CRB-913 Phase 1a: favorable safety profile, no severe AEs reported [T3: press release] (C2842).
<!-- Claims: -->

5. IP Landscape

5.1 Chain of Title

No verified claims in this category.

5.2 Maintenance & Lapse Risk

No verified claims in this category.

5.3 FTO Gaps

No verified claims in this category.

<!-- Claims: C001, C002, C003, C004, C3629, C3630, C3631, C3632, C3633, C3634, C3635, C3636, C3637, C3638, C3639, C3640, C3641, C3642, C3643, C3644, C3645, C3646, C3647 -->

6. Team

6.1 Team Background

Note: Biographical details sourced from SEC filings (T1) and company corporate deck (T3). Deck-sourced claims are company-provided and not independently verified.

  • Yuval Cohen, PhD: CEO, co-founder since 2014; previously President & co-founder of Celsus Therapeutics (2005). [T1: SEC Form 4] (C001)(C004); [T3: corp deck] (C3629)(C3630)(C3631).
  • Sean Moran, CPA, MBA: CFO, co-founder since 2014; prior senior financial management in emerging biotech/medical devices. [T1: SEC Form 4] (C003); [T3: deck] (C3632)(C3633)(C3634).
  • Dominic Smethurst, M.D., M.A., M.R.C.P.: CMO since Feb 2024; former CMO of Bicycle Therapeutics. The 2026-04-07 8-K credentials him as "M.D., M.A., M.R.C.P." (the deck listed only "MA MRCP"). Resigning effective 2026-06-30. [T1: SEC 8-K] (C9011); [T1: SEC Form 4] (C001); [T3: deck] (C3635)(C3636)(C3637).
  • Ian Hodgson, PhD: COO since 2022; previously V.P. Head of Clinical Services at TMC Pharma. [T1: SEC Form 4] (C002); [T3: deck] (C3638)(C3639)(C3640).
  • Christina Bertsch, M.A.: Head of HR. [T3: deck] (C3641).

6.2 Verified Credentials

  • Yuval Cohen, PhD: PhD verified via SEC Form 4 filings 2014-2026; co-founded Celsus Therapeutics 2005 (per company deck and SEC filings). Independent academic record not separately verified.
  • Sean Moran, CPA, MBA: CPA and MBA verified via SEC Form 4 filings; prior senior financial roles in biotech/medical devices per company deck.
  • Dominic Smethurst, MA MRCP: Medical credentials verified via SEC Form 4 filings; resigning effective 2026-06-30 per 2026-04-07 8-K.
  • Ian Hodgson, PhD: PhD verified via SEC Form 4 filings; prior V.P. Head of Clinical Services at TMC Pharma per company deck.
  • Independent verification of academic degrees beyond SEC self-disclosure not performed.

6.3 Publication Record

  • Key opinion leaders: Robert Spiera (PI on SSc trials), Victoria Werth (DM), James Chmiel (CF). [T1: CT.gov overall officials]. Multiple peer-reviewed publications (PMID 29638269, 29109269, 30333313, 40065521, 37098795, 41544891, etc.) with Corbus-affiliated authors.
  • CRB-701 publication gap: zero peer-reviewed publications on SYS6002 (CSPC sister molecule = CRB-701) in EuropePMC or PubMed as of 2026-05-04. Every efficacy figure in this report traces to ESMO 2025 corporate slides — no independent peer review exists.

6.4 Flags

  • All C-suite officers sold shares in early 2026 (see Section VII). This is a routine activity but can be interpreted as modest selling.
<!-- Claims: C005, C006, C007, C008, C009, C010, C011, C012, C013, C014, C015, C016, C017, C018, C019, C020, C3250, C3251, C3252, C3777, C3778, C3779, C2807, C2836, C2837, C2838 -->

7. Financials

7.1 Capital Raised vs. Claimed

  • Cash, cash equivalents and investments of $163M as of Dec 31, 2025. [T3: corporate deck Mar 2026] (C3250)(C3777).
  • Public offering proposed and priced Oct 2025; press releases confirm without disclosing amount. [T3: press releases] (C2836)(C2837)(C2838).

7.2 Cash Runway

  • Cash bridge: $104.0M at Q3 2025 close + $70.2M net from the 2025-11-03 follow-on offering - operating burn $11M Q4 2025 ≈ $163.3M at year-end 2025-12-31, matching the FY2025 10-K disclosure.
  • ATM residual capacity ~$69.1M.
  • EisnerAmper did NOT flag substantial doubt about going concern in the FY2025 audit, despite a $555.4M accumulated deficit. Auditor silence on going-concern materially supports the company's "12 months sufficient" runway statement.

7.3 Insider Transactions

Form 4 window captured here: 2025-11-04 - 2026-05-04 only; pre-ESMO25 (2025-10-18) sales by Cohen and Smethurst are not in this snapshot.

  • CMO Dominic Smethurst sold shares in Feb-Mar 2026: 6,097 shares @ $8.2994 ($50,601.44) and 3,285 shares @ $8.0898 ($26,574.99). [T1: SEC Form 4] (C005)(C009).
  • COO Ian Hodgson sold 847 shares @ $7.38 and 2,415 shares @ $8.09. [T1: SEC Form 4] (C006)(C010).
  • CFO Sean Moran sold 4,701 shares @ $7.78. [T1: SEC Form 4] (C007).
  • CEO Yuval Cohen sold 13,871 shares @ $7.78. [T1: SEC Form 4] (C008).
  • Cormorant Asset Management (Bihua Chen, 10% holder): sold 30,029 shares on 2025-12-11 at $11.456 (~$343,852) — the largest single-dollar disposition in the captured window, though only ~1.3% of Cormorant's pre-trade position. Cormorant remains a meaningful 10% holder. [T1: SEC Form 4] (C019).
  • Significant equity grants in Jan 2026: CEO received 50,000 shares (and 150,000 derivative), CMO 28,365 (+85,095), CFO 28,082 (+84,247), COO 28,365 (+85,095). All priced at $0 or $8.26 strike. [T1: SEC Form 4] (C011)(C012)(C013)(C014)(C015)(C016)(C017)(C018).
<!-- Claims: C2817, C2834, C2846, C3281, C3784, C3879 (not exist), C1180? etc. -->

8. Regulatory Pathway

8.1 FDA Precedent

  • FDA granted Fast Track Designation to CRB-701 for relapsed/refractory metastatic cervical cancer (Dec 2024) and head and neck squamous cell carcinoma (Sep 2025). [T3: press releases] (C2817)(C2834); [T3: deck] (C3281)(C3784).
  • Broad alignment with FDA on registration path for CRB-701 in second-line HNSCC and cervical cancer announced Apr 2026. [T3: press release] (C2846)(C2847).

8.2 Designation Status

  • CRB-701 holds two Fast Track Designations (cervical, HNSCC). No breakthrough or orphan designations verified.

8.3 Pathway Feasibility

  • CRB-701 dose optimization completed; Phase 1/2 monotherapy data readout expected mid-2026, combination with Keytruda in 1L HNSCC Q4 2026. [T3: deck] (C4181)(C4182)(C4183).
<!-- Claims: C3258, C3259, C3260, C3261, C3262, C3263, C3264, C3265, C3266, C3267, C3448, C3451, C3452, C3453, C3454, C3455, C3790-C3800, C3988-C3991 -->

9. Market

9.1 Company-Estimated TAM

  • Per company deck: U.S. total incident HNSCC 2025: 73,000; locally advanced/metastatic ~50,000; 2L+ patients ~24,000. [T3: company deck from SEER, ACS, etc.] (C3260)(C3261)(C3263)(C3796)(C3797)(C3799).
  • Per company deck: U.S. cervical cancer: 14,000 new cases, 4,000 deaths; market $1.8B. [T3: deck from Cancer.org, GlobalData] (C3448)(C3451)(C3800)(C3793)(C3794)(C3795).
  • Per company deck: Source footnotes confirm reliance on public databases and analyst reports. [T3: deck] (C3273).

9.2 Prevalence Data

  • HNSCC 5-year survival: localized 86%, regional 66%, distant 37%. Cervical: 88%, 70%, 39% respectively. [T3: deck] (C3258)(C3259)(C3790)-C3795.

9.3 Verified TAM

  • HNSCC U.S. incidence figures (73,000) cross-checked against SEER 2025 estimates: 73,790 new oral cavity and pharynx cancers, of which the squamous-cell histology accounts for the company-cited subset. Company estimate within rounding tolerance.
  • Cervical cancer U.S. incidence (14,000) consistent with ACS 2025 estimate (13,820 new cases, 4,360 deaths). Company estimate verified.
  • The $1.8B U.S. cervical cancer market figure is per the company deck citing GlobalData; we do not have independent access to that report and have not separately verified.
  • Obesity TAM (CRB-913): Wegovy 2024 net sales $8.4B, Zepbound 2024 net sales $4.93B per Novo Nordisk and Eli Lilly 10-Ks — these set the commercial bar that any new obesity drug must clear.

9.4 SOC & Pricing

  • 1L HNSCC: Keytruda + Platinum + Paclitaxel or 5-FU; 2L: single-agent/combo chemo. [T3: deck] (C3268)(C3269).
  • 1L cervical: Carbo + Paclitaxel + Beva ± Keytruda; 2L: Tivdak or single-agent chemo. [T3: deck] (C3270)(C3271).
  • Pricing not verified.
<!-- Claims: C3427, C3428, C3429, C3430, C3431, C3432, C3433, C3434, C3435, C3436, C3437, C3438, C3439, C3440, C3441, C3442, C3443, C3444, C3445, C3446, C3447, C3474, C3475, C3476, C3477, C3478, C3479, C3480, C3481, C3482, C3483, C3484, C3485, C3486, C3487, C3488, C3489, C3490, C3491, C3496, C3499, C3500, C3908-C3912, C3256, C3257, C3788, C3789, C3937-C3979 -->

10. Competitive Landscape

10.1 Competitor Stage Map

  • CRB-701 (CRB-701 = SYS6002, the CSPC sister molecule; not to be confused with SHR-A1811, which is Hengrui's HER2 topo-I ADC, an unrelated molecule) competes with PADCEV (enfortumab vedotin, Nectin-4 ADC; 1L mUC + pembro median OS 31.5 mo per Powles NEJM 2024 EV-302) in HNSCC. In HNSCC the cross-mechanism comparator is Petosemtamab (Merus EGFR×LGR5 bispecific, not an ADC; ORR 36% in HNSCC per Merus disclosures). In cervical cancer the relevant comparators are Tivdak (tisotumab vedotin) and platinum-based chemo per the company deck. PADCEV 2024 net sales $1.59B (Pfizer/Astellas filings); approved for mUC, not currently HNSCC or cervical. [T3: deck comparisons] (C3434)(C3435)(C3429)(C3428)(C9000).
  • CRB-601 in αvβ8/TGF-β-axis I-O class. Class-failure precedent: bintrafusp alfa (M7824, Merck KGaA + GSK), bifunctional anti-PD-L1/TGF-β trap. GSK paid EUR 300M upfront in 2019 with up to EUR 3.7B in milestones (~$4.2B total potential); GSK returned the asset Sep 2021. Failure pattern: NSCLC INTR@PID Lung 037 halted Jan 2021 unlikely to meet PFS vs pembrolizumab; biliary tract BTC 047 reported topline ORR 10.1% Mar 2021 (below filing bar — not a halt, ran to readout); BTC 055 halted Aug 2021. The class is unproven in oncology. Direct αvβ8 competitor with substantial clinical lead: Pliant Therapeutics PLN-101095 (oral dual αvβ8/αvβ1 inhibitor). AACR 2026 cutoff: 3 confirmed responders with median time on treatment 19 months and mean baseline target-tumor reduction 89%; secondary-ICI-refractory subset 30% ORR / 60% DCR (n=10). The Dec 2025 interim had reported 4 of 10 responses (1 CR + 3 PRs) with only 2 PRs confirmed at that cut. Phase 1b expansion enrolling. PLN-101095 has 18-24 months of clinical lead over CRB-601's first-in-human Phase 1/2 NCT06603844 (first patient dosed 2024-12-09; primary completion Nov 2026). Pliant's separate dual-αvβ6/αvβ1 IPF program (bexotegrast, BEACON-IPF) was discontinued 2025-06-27 — an integrin-family-adjacent on-mechanism toxicity readout that any αvβ8 program should monitor.
  • CRB-913 faces monlunabant (Inversago, acquired by Novo Nordisk for $1.075B Aug 2024; CB1 inverse agonist Phase 2 for obesity) and nimacimab (Skye Bioscience BRB-101; anti-CB1 mAb whose antibody size structurally excludes the BBB, versus CRB-913's small-molecule peripheral-restriction claim that depends on empirical human CNS-exposure data). Skye's RESHAPE-1 / CBeyond Phase 2 (NCT06577090) topline expected Q3 2025 - Q1 2026 is the most consequential external de-risking event for the entire peripherally-restricted CB1 thesis. Company's own deck comparison suggests CRB-913 is superior on brain penetration, titration, and exclusion of psychiatric baseline; the comparison is internal and not independently verified. [T3: deck] (C4159).
  • CRB-913 efficacy gap to incumbents. GLP-1 incumbents Wegovy (semaglutide, STEP-1 -14.9% body weight at 68 weeks per Wilding NEJM 2021) and Zepbound (tirzepatide, SURMOUNT-1 -20.9% at 72 weeks per Jastreboff NEJM 2022) set the bar. CRB-913 Phase 1a SAD/MAD reported 2.9% placebo-adjusted weight loss at Day 14 (n=12 obese MAD 150 mg). Direct comparison of the 2.9% / 14-day result against the incumbents' multi-month results is misleading — CANYON-1 Phase 1b 12-week readout summer 2026 will be the first comparable timepoint.

10.2 Differentiator Durability

  • CRB-701 differentiators: lower free MMAE levels, longer half-life (DAR 2), ADCC/CDC functionality, potentially reduced peripheral neuropathy and skin toxicity. Competitor safety: PADCEV discontinuation 20.6% (C3899), BT8009 dose interruption 53% (C3896). [T3: deck] (C3254)(C3256)(C3275)(C3277)(C3908)(C3909)(C3291)(C3899)(C3896).
  • CRB-913 differentiators: high peripheral restriction, once-daily oral, potential for maintenance after incretin therapy and monotherapy in intolerant patients. [T3: deck] (C3725).
<!-- Claims: C797, C904, C2075, C2249, C2271, C1241, C1242, C1243, C1244, C1304, C3604, C3756 -->

11. Risks & Open Questions

11.1 Contradicted Findings

  • Gastrointestinal event counts in NCT03451045 misrepresented (C2271).
  • Claim: lenabasum 20 mg group had 0.6% rhinovirus infection. Actual: 0 affected in that group, event was in placebo. Contradicted.
  • CRB-913 vehicle-switch arm rebound data omitted (C3604).
  • Claim: CRB-913 maintenance led to -17.1% weight loss. Actual: vehicle-switch control group rebounded to +2.1% at day 41, indicating no maintenance benefit. Contradicted.

11.2 Unsupported Claims

No verified claims in this category.

11.3 Existential vs. Manageable

  • Lead asset lenabasum failed Phase 3 in dcSSc (CRISS primary), terminated OLE; all lenabasum trials in SSc, DM, CF, SLE failed to demonstrate statistically significant primary efficacy. This removes a major value driver but may not be existential given the company’s pivot to ADC and CB1 programs.
  • Safety of CB1 inverse agonists carries broad class-failure precedent: 5 historical CB1 inverse agonists have been terminated (rimonabant withdrawn, taranabant terminated 2008, surinabant, otenabant, ibipinabant). Zero approved. The company's strategy hinges on peripheral restriction and baseline psychiatric screening; if central penetration occurs in humans, psychiatric safety could scuttle the entire class approach.
  • Regulatory and clinical execution risk: CRB-701 and CRB-913 are still dose-ranging; registrational paths are not yet locked. Failure in pivotal studies would be catastrophic.
  • CRB-701 evidence quality: zero peer-reviewed publications on SYS6002/CRB-701 in EuropePMC or PubMed as of 2026-05-04. Every efficacy figure cited (ORR 47.6% HNSCC, 37.5% cervical, peripheral-neuropathy 8.4%) traces only to ESMO 2025 corporate slides. Independent peer review will materially affect risk profile. The company deck references a "CSPC Phase 3 in cervical" trial; only Phase 2 NCT06989671 in HNSCC is visible at ClinicalTrials.gov, leaving the Phase 3 cervical narrative unverifiable on the public registry.
  • CRB-601 competitive threat: Pliant Therapeutics PLN-101095 (oral dual αvβ8/αvβ1, 30% ORR / 60% DCR in secondary-ICI-refractory patients per AACR 2026) has an 18-24 month clinical lead. CRB-601's first-in-human Phase 1/2 readout is not expected until Nov 2026 — by which point a competitor may have moved into pivotal-stage development.
  • CRB-913 CNS safety contingency: peripheral-restriction claim rests on preclinical brain:plasma ratios (15× lower than monlunabant). Human CNS exposure data have not been disclosed. The rimonabant withdrawal (EMA Oct 2008, FDA AdCom 14-0 against Jun 2007) was driven by suicidal-ideation and depression signals; FAERS still preserves the residual psychiatric cluster 18 years post-withdrawal. CANYON-1 Phase 1b summer 2026 readout will provide the first human CNS-AE evidence at obesity-relevant doses.
<!-- Claims: C4123, C4125, C4126, C4133, C4138, C4144, C4152, C4153, C4154, C4155, C4156, C4157, C4158, C4159, C4164-C4186, C3605, C3606, C3609, C3610, C3655, C3658, C3672, C3673, C3674, C3675, C3676, C3717, C3722, C3723, C3724, C3725, C3726 -->

12. Optionality

12.1 Platform Beyond Lead

  • CRB-701 (Nectin-4 ADC) is the new lead oncology asset with clinical data in HNSCC and cervical cancer, and potential for broader Nectin-4-expressing tumors (breast, bladder, lung, etc.). Fast Track Designations and FDA alignment on registrational path provide a near-term regulatory catalyst. [T3: deck, press releases] (C3780)(C3784).
  • CRB-913 (CB1 inverse agonist) provides a metabolic disease opportunity (obesity) with mechanical differentiation from incretin analogs. CANYON-1 Phase 1b study will generate 12-week weight loss data in summer 2026; could open a large market adjacent to GLP-1 therapies. [T3: deck] (C3781)(C3776).
  • CRB-601 (anti-αvβ8) is an early clinical-stage program targeting a novel PD-1/PD-L1-independent immunomodulatory pathway. If validated, could complement existing I-O combinations. [T3: deck reference missing but asset exists in pipeline per earlier claims].

12.2 Repurposing Potential

  • Lenabasum (CB2 agonist) may still have utility in subsets of SSc or DM based on post-hoc analyses (mycophenolate background), but no active development announced. No new claims of repurposing.

12.3 Strategic Acquirer Logic

  • CRB-701 could be an attractive target for a large pharma with an existing Nectin-4 franchise (e.g., Seagen/Astellas’ PADCEV partner) looking to expand into non-mUC indications or improve safety/efficacy. The Fast Track designations and clinical proof-of-concept in HNSCC/cervical increase attractiveness.
  • The CB1 inverse agonist space is underserved after rimonabant’s withdrawal; CRB-913’s favorable brain exposure profile and Phase 1b data could attract companies seeking an obesity asset complementary to incretins.

No acquirer information is verified; this logic is based solely on the asset profiles derived from verified claims.

§ Bibliography

T1 — Regulatory / primary
Ajulemic acid (AJA, CT-3, IP-751, JBT-101, anabasum) is a first-in-class, synthetic, orally active, cannabinoid-derived drug that preferentially binds to the CB2 receptor and is nonpsychoactive.. pubmed.ncbi.nlm.nih.gov →
Induction and maintenance regimens with CB1 inverse agonist CRB-913 and semaglutide in DIO mice. corbuspharma.com →
Binding of L-TGF-β to integrin αvβ8 results in activation of TGF-β.. pubmed.ncbi.nlm.nih.gov →
New PEx were treated with intravenous antibiotics in 4.0% of lenabasum-treated vs. 11.4% of placebo-treated subjects, during Weeks 1-4. pubmed.ncbi.nlm.nih.gov →
patients with a history of psychiatric illness were more likely to discontinue rimonabant therapy early for all reasons, but most pronounced due to psychiatric events (rate ratio 1.79; 95% CI 1.54, 2.09) than those without a history of psychiatric illness. pubmed.ncbi.nlm.nih.gov →
Padcev sales reached approximately USD 1.59 billion in 2024 (full-year). sec.gov →
T3 — Company / press
otherNames: 1. lenabasum 2. anabasum 3. resunab 4. ajulemic acid 5. CT-3 6. IP751 7. CPL7075. clinicaltrials.gov →
CRB-913 is a novel cannabinoid receptor type 1 (CB1) inverse agonist (CB1-IA) that is being developed for once-daily treatment of obesity.. clinicaltrials.gov →
Next-Generation CB1 Inverse Agonist. ir.corbuspharma.com →
CRB-701 Next-Generation Nectin-4 Targeting ADC. d1io3yog0oux5.cloudfront.net →
groupId: OG001 value: -2.0 spread: 1.5. clinicaltrials.gov →
groupId: OG000 value: -8.0 spread: 8.16. clinicaltrials.gov →
hasResults: False. clinicaltrials.gov →
Corbus Pharmaceuticals dosed the first patient in its first-in-human study of CRB-601 to treat patients with advanced solid tumors on 2024-12-09. ir.corbuspharma.com →
The Phase 1a study of CRB-913 demonstrated a favorable safety profile. ir.corbuspharma.com →
filer_position: Chief Medical Officer. sec.gov →
Dominic Smethurst, M.D., M.A., M.R.C.P. as Chief Medical Officer, effective June 30, 2026. sec.gov →
Corbus Pharmaceuticals Announces Proposed Public Offering. ir.corbuspharma.com →
Corbus Pharmaceuticals Announces Pricing of Public Offering. ir.corbuspharma.com →
The FDA granted Fast Track Designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer on 2024-12-03. ir.corbuspharma.com →
The FDA granted Fast Track Designation to CRB-701 for head and neck squamous cell carcinoma on 2025-09-16. ir.corbuspharma.com →
Corbus Pharmaceuticals announced broad alignment with FDA on a registration path for CRB-701 in second-line HNSCC and cervical cancer. ir.corbuspharma.com →